A regulatory rebuff in the USA has hampered Brussels, Belgium-based biotech UCB (Euronext: UCB) in its quest to market bimekizumab in plaque psoriasis.
Shares in the company were down nearly a fifth on Friday, after it was revealed that the US Food and Drug Administration had sent the firm a Complete Response Letter (CRL) regarding its submission.
The delay comes on top of a prior deferral, in October 2021, with the FDA at that time blaming COVID-19-related travel restrictions for its inability to reach a verdict.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze